Journal of Leukemia
Open Access
ISSN: 2329-6917
ISSN: 2329-6917
Chief Medical Advisor, WeHeal Foundation, Los Gatos, California, USA
Review Article
Acute Myelogenous Leukemia: Pathogenesis, Modern Therapies, and Future Directions
Author(s): Abhit Singh*
Acute Myelogenous Leukemia (AML) is an aggressive hematologic malignancy characterized by clonal proliferation of myeloid precursors with impaired differentiation. This review provides a comprehensive overview of AML etiology, molecular pathophysiology, current treatment strategies, and emerging therapies, with a focus on United States clinical practice. We detail known risk factors for AML, including antecedent hematologic disorders, genetic predispositions, environmental and iatrogenic exposures, while noting most cases are de novo without a clear cause. The complex molecular biology of AML is discussed, highlighting key cytogenetic abnormalities and mutations (FLT3, NPM1, TP53, IDH1/2, DNMT3A, etc.) that drive leukemogenesis and inform prognostic risk stratification. Standard induction chemotherapy (e.g. 7+3 cytarabine plus anthracycline) and consolidation with high-dose c.. View More»